- Current report filing (8-K)
07 Septembre 2010 - 6:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
September 7, 2010
AXM PHARMA, INC.
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
001-31886
|
|
20-0745214
|
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
|
|
|
|
|
|
20955 Pathfinder Road, Suite 100
Diamond Bar, CA 91765
|
|
10011
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
|
|
|
|
|
|
Registrant’s telephone number, including area code:
(646) 393-4365
|
|
|
|
|
|
|
|
|
|
N/A
|
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(b) Resignation of Director
On September 1, 2010,
Mr. Elliot Maza
resigned from his position as a director of AXM Pharma, Inc. (the “Company”).
Mr. Maza did not
note any disagreement with the Company concerning any matter relating to the Company’s operations, policies or practices as a reason for his resignation.
In connection with Mr. Maza’s resignation, the Company entered into a separation agreement (the “Separation Agreement”) with Mr. Maza and issued a warrant to Mr. Maza (the “Warrant”). The Separation Agreement and the Warrant are filed as Exhibit 10.1 and Exhibit 10.2 hereto, respectively, and incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit No.
|
|
Description
|
|
|
|
Separation Agreement, by and between the Company and Elliot Maza, dated September 1, 2010.
|
|
|
|
Warrant, by and between the Company and Elliot Maza, dated September 1, 2010.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
AXM PHARMA, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Wei-Shi Wang
|
|
|
Dated: September 4, 2010
|
|
|
Wei-Shi Wang
|
|
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
EXHIBIT INDEX
|
Exhibit No.
|
|
Description
|
|
10.1
|
|
Separation Agreement, by and between the Company and Elliot Maza, dated September 1, 2010.
|
|
10.2
|
|
Warrant, by and between the Company and Elliot Maza, dated September 1, 2010.
|
AXM Pharma (CE) (USOTC:AXMP)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
AXM Pharma (CE) (USOTC:AXMP)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
